Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in Solid Tumors With NRG1 Fusion
NCT06383884Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of patritumab deruxtecan in solid tumor, sponsored by Samsung Medical Center. Started Aug 2024; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06383884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383884.